Testosterone based dosing regimen of goserelin in patients with prostate cancer

Phase 4

Completed

• Conditions: Prostate cancer; prostate tumour; 10038588; 10036958

• Registration Number: NL-OMON54398
• Lead Sponsor: Franciscus Gasthuis & Vlietland

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 30

Inclusion Criteria

- Informed consent
- >= 18 years
- Diagnosed with prostate cancer with an indication for Androgen Deprivation
Therapy (>= 2 years or permanently)

Exclusion Criteria

- Patients with a history of hypersensitivity to LHRH agonists
- Patients not able to visit hospital*s laboratory for blood sampling
- Patients with a serum testosterone > 1.2 nmol/L while treated with LHRH
therapy (patients who fail on LHRH therapy, in the first half year of treatment)
- Concurrent systemic anti- cancertherapy other than goserelin

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary endpoint of this study is the percentage (%) of patients for whom<br /><br>the dosing interval before the fourth goserelin 10.8<br /><br>mg injection can safely be extended with 4 weeks using a testosterone based<br /><br>dosing regimen. </p><br>